FIELD: chemistry.
SUBSTANCE: invention relates to a novel compound - N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1H-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulphonamide of formula A and/or a pharmaceutically acceptable salt thereof, having KDR and/or FGFR1 inhibitor properties. The compounds can be used to treat disorders associated with KDR mediated angiogenesis, such as cancer and age-related macular degeneration, or various cancerous diseases which respond to FGFR1 inhibition. Compound (A) corresponds to the structural formula (A) 
given below.
EFFECT: invention relates to crystalline forms I and II of said compound A and methods for production thereof, pharmaceutical compositions and a method of treatment.
38 cl, 8 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | 2016 |
|
RU2712187C2 |
| PYRIMIDINE DERIVATIVES | 2008 |
|
RU2455994C2 |
| HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | 2017 |
|
RU2742115C2 |
| HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | 2007 |
|
RU2463301C2 |
| BICYCLIC AMINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | 2007 |
|
RU2465275C2 |
| NEW DERIVATIVE OF PYRIDO [3,4-d] PYRIMIDINE-8-ONE WITH PROTEIN KINASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, CONTAINING ABOVE DERIVATIVE | 2020 |
|
RU2780168C1 |
| 2,6-SUBSTUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | 2005 |
|
RU2417990C2 |
| DERIVATIVES OF 4-AMINO-6-PHENYLPYRROLO[2,3]PYRIMIDINE POSSESSING INHIBITORY EFFECT ON TYROSINE KINASE ACTIVITY, THEIR USING AND METHODS FOR THEIR PREPARING (VARIANTS) | 2002 |
|
RU2318826C2 |
| PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE PREVENTION OR TREATMENT OF CANCER | 2019 |
|
RU2807277C2 |
| 6-ARYL-4-MORPHOLINE-1-YL PYRIDONES SUITABLE FOR TREATMENT OF CANCER OR DIABETES | 2017 |
|
RU2754664C2 |
